Cargando…

Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report

INTRODUCTION: Leptomeningeal dissemination due to HER2-overexpressing breast cancer is a rare and hard to treat complication with short-term dismal prognosis. PATIENT CONCERNS: A 34-year-old female previously treated because of HER2+ breast cancer is admitted to the Neurology Department in December...

Descripción completa

Detalles Bibliográficos
Autores principales:	García, Francisco José Valdivia, Carrión, Natalia Palazón, de la Cruz-Merino, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	5750
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946348/ https://www.ncbi.nlm.nih.gov/pubmed/31895768 http://dx.doi.org/10.1097/MD.0000000000018298

Ejemplares similares

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
por: Park, Won-Young, et al.
Publicado: (2016)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab
por: Wang, Xinle, et al.
Publicado: (2019)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment
por: Ren, Xiaofei, et al.
Publicado: (2023)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
por: Gulia, Seema, et al.
Publicado: (2016)

A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy
por: Ji, Dongmei, et al.
Publicado: (2020)

Methodological quality evaluation of systematic reviews or meta-analysis of trastuzumab-based therapy for breast cancer: A systematic review
por: Wei, Hua, et al.
Publicado: (2021)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
por: Lu, Nu T., et al.
Publicado: (2015)

Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment
por: Watanuki, Rurina, et al.
Publicado: (2020)

HER2-positive pure mucinous breast carcinoma: A case report and literature review
por: Zhao, Xingjuan, et al.
Publicado: (2020)

Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis
por: Lin, Yuxiang, et al.
Publicado: (2020)

Diagnosis and treatment of advanced HER2-positive breast cancer in young pregnant female: A case report
por: Tang, Tiantian, et al.
Publicado: (2020)

Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction
por: Wu, Wei, et al.
Publicado: (2016)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer
por: Chen, Jim-Ray, et al.
Publicado: (2017)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: A SEER-based study
por: Wu, Jiangwen, et al.
Publicado: (2022)

Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: A case report
por: Cao, Yong, et al.
Publicado: (2019)

Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study
por: Yang, Xuan, et al.
Publicado: (2022)

LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS
por: Trevino, Christopher R, et al.
Publicado: (2019)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
por: Lazaratos, Anna-Maria, et al.
Publicado: (2023)

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
por: Jiao, Xiao-Dong, et al.
Publicado: (2018)

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
por: Tao, Miaomiao, et al.
Publicado: (2017)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

Complete response of leptomeningeal carcinomatosis secondary to breast cancer
por: Troussier, Idriss, et al.
Publicado: (2020)

Pulsed Erlotinib as Sole Treatment of Leptomeningeal Carcinomatosis: Can We Avoid the Use of Intrathecal Therapy?
por: Santhosh-Kumar, Cheruppolil R., et al.
Publicado: (2014)

Can we cure stage IV triple-negative breast carcinoma?: Another case report of long-term survival (7 years)
por: Chue, Ben Man-Fai, et al.
Publicado: (2019)

Complete Eye Ophthalmoplegia: the unusual initial presentation of Leptomeningeal Carcinomatosis
por: Chauhan, Lakshpaul, et al.
Publicado: (2019)

Relationship between perimetric increase and fluoroscopic pattern type in secondary upper limb lymphedema observed by Indocyanine green lymphography
por: Medina-Rodríguez, María Elena, et al.
Publicado: (2020)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

SDPS-16 CYTOLOGIC AND SEROLOGIC RESPONSE WITH INTRATHECAL METHOTREXATE IN A PATIENT WITH LEPTOMENINGEAL CARCINOMATOSIS FROM OVARIAN CANCER
por: Cordova, Christine, et al.
Publicado: (2023)

Recent Advancements of Treatment for Leptomeningeal Carcinomatosis
por: Gwak, Ho-Shin, et al.
Publicado: (2015)

Leptomeningeal Carcinomatosis with Delayed Ocular Manifestations
por: Czyz, Craig, et al.
Publicado: (2021)

Leptomeningeal carcinomatosis or ischemic cerebrovascular disease?
por: Eran, Ayelet, et al.
Publicado: (2021)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Vitamin D Receptor Polymorphism and Breast Cancer Risk: A Meta-Analysis
por: Lu, Demin, et al.
Publicado: (2016)

Intratumoral Agreement of High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopic Profiles in the Metabolic Characterization of Breast Cancer
por: Park, Vivian Youngjean, et al.
Publicado: (2016)

Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database: Matched-Pair Analysis of Patients With Female Breast Cancer
por: Choi, Min-Young, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qitcke4dliivia4l29eg8j9659